G-BA rules Jetrea (Thrombogenics) offers significant benefit in VMT
The German Federal Joint Committee (G-BA) has concluded that Jetrea (ocriplasmin), from Thrombogenics, demonstrates significant added benefit for Vitreomacular Traction (VMT) patients with mild and moderate symptoms (94% of patients covered by approval) when compared with existing comparative treatment. G-BA particularly considered the potential improvement in visual acuity and the avoidance of surgery in the back of the eye by Jetrea as beneficial for patients.
G-BA's final guidance confirms the recommendation made by the German Institute for Quality and Efficiency in Health Care (IQWiG) in August 2013. Jetrea is to-date one of only six medicines appraised by G-BA to provide significant additional therapeutic benefits for patients.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins